Treatment of Non-resectable Bile Duct Cancer With Radiofrequency Ablation or Photodynamic Therapy
Status:
Not yet recruiting
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
Bile duct cancer is often diagnosed after curative options are no longer available. Stent
therapy is used to keep the ducts open and can be combined with photodynamic therapy (PDT) to
extend life expectancy. PDT requires an injection of photosensitizer after which light of a
particular wavelength is applied endoscopically to kill the cancer cells. Drawbacks include
not only high costs and poor availability, but foremost that patients have to avoid direct
sunlight for a period of weeks. Radio frequency ablation (RFA) together with stent
implantation constitutes an alternative by which the cancer cells are killed through heat,
also applied endoscopically. The RFA technology is more widely available and easier to
deploy. However, it has not been studied extensively and no randomized trials exist comparing
the two methods. This trial will compare survival in patients with a particular bile duct
cancer depending on whether they receive PDT or RFA. Moreover, data will be collected on
side-effects and quality of life.